The Liver Foundation has welcomed highly respected business leader and health professional Dr Lynne Pezzullo as its new Chair. Dr Pezzullo has a passion for health and wellbeing, bringing an impressive list of accomplishments and credentials to her new role.
Dr Pezzullo founded and led the Health Economics and Social Policy team for Access Economics, before heading Australia’s largest health economic practice with Deloitte Australia. She has published multiple reports and publications on liver disease and liver cancer, and has an extensive network among the health sector and policy-makers. Having served on 20 boards over 27 years, she will call upon her depth of experience and business acumen to lead the Foundation’s Board through a new phase of growth.
Dr Pezzullo officially takes over in October 2021 from outgoing Chair Mr Ben Richardson. Richardson has served as a director on the Board for almost 10 years and as Chair of the Liver Foundation since 2018. The Liver Foundation CEO Richard Wylie said he looked forward to working with Dr Pezzullo to champion the changes needed to drive down liver disease and better support those affected. “I am delighted to welcome Dr Pezzullo to the Foundation and I’d like to thank Ben Richardson for his outstanding leadership as the Foundation’s Chair,” he said.
Dr Pezzullo said she was excited about taking on such an important role in a growing organisation focussed on improving health outcomes for thousands of Australians. “It is a real privilege to be appointed the Chair of the peak not-for-profit community organisation in Australia for people affected by, or at risk of liver disease,” she said. “The Liver Foundation is at an exciting time in its journey, and I am delighted to be part of its next phase. I’ve also been personally touched by liver disease, having seen its devastating impact on my dear aunt, who died too young from a condition that hopefully in future is more preventable and treatable.
“As for my vision of the Liver Foundation, I hope to work with the other Board members, the CEO, ANLCC collaborators and other stakeholders to significantly increase awareness, funding, research, treatment and support for people with liver disease, and their families and carers.”
Readers also enjoyed our story about Gillian Eldershaw ILGA Board